Previous 10 | Next 10 |
Successful completion of dose-escalation stage of ongoing Phase 1/2 clinical study; OP-1250 demonstrated highly attractive pharmacokinetics, favorable tolerability, and clear efficacy signals Robust anti-tumor activity, including three partial responses (two confirmed and one ...
Olema Pharmaceurticals (NASDAQ:OLMA) says that there is "falsified information" circulating on social media dealing with a poster presentation on breast cancer candidate OP-1250 at an upcoming medical conference. Trading in the stock was halted at 3:23p ET and did not resume before the market...
SAN FRANCISCO, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women...
Interim pharmacokinetic, safety and tolerability, and preliminary efficacy data from Phase 1 dose escalation to be presented Company to host investor webcast at 8:30 a.m. ET on Wednesday, December 8, 2021 SAN FRANCISCO, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Olema P...
Gainers: Longeveron (NASDAQ:LGVN) +36%, SCYNEXIS (NASDAQ:SCYX) +16%, Context Therapeutics (NASDAQ:CNTX) +15%, Akoya Biosciences (NASDAQ:AKYA) +15%, Aspira Women's Health (NASDAQ:AWH) +15%. Losers: Connect Biopharma (NASDAQ:CNTB) -54%, Flora Gr...
Olema Pharmaceuticals (NASDAQ:OLMA): Q3 GAAP EPS of -$0.45 beats by $0.01. Press Release. For further details see: Olema Pharmaceuticals EPS beats by $0.01
Completed dose-escalation stage of Phase 1/2 clinical trial of OP-1250 in patients with metastatic, ER+ / HER2- breast cancer Interim safety, tolerability, pharmacokinetic and initial efficacy data from Phase 1 dose escalation to be presented at 2021 San Antonio Breast...
SAN FRANCISCO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women...
Radius Health (RDUS +15.2%) has recorded the biggest intraday gain since May to reach a three-month high after the company announced that its experimental therapy elacestrant met the primary endpoint in a late-stage trial for certain patients with breast cancer. Out-licensed to Menarini ...
Gainers: Sesen Bio (NASDAQ:SESN) +43%, Radius Health (NASDAQ:RDUS) +29%, Valneva SE (NASDAQ:VALN) +15%, Olema Pharmaceuticals (NASDAQ:OLMA) +15%, First Wave BioPharma (NASDAQ:FWBI) +6%. Losers: ATI Physical Therapy (NYSE:ATIP) -20%, HCW Biologics (...
News, Short Squeeze, Breakout and More Instantly...
Olema Pharmaceuticals Inc. Company Name:
OLMA Stock Symbol:
NASDAQ Market:
Olema Pharmaceuticals Inc. Website:
2024-06-13 17:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-04 15:30:03 ET Oppenheimer analyst issues OUTPERFORM recommendation for OLMA on June 4, 2024 02:10PM ET. The previous analyst recommendation was Outperform. OLMA was trading at $14.4 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) is one of today's top gainers. The company's shares have moved 17.73% on the day to $13.84. Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's ...